公开(公告)号：US10881677B2

公开(公告)日：2021-01-05

申请号：US15770437

申请日：2016-10-24

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K31/704 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.

公开(公告)号：US09889180B2

公开(公告)日：2018-02-13

申请号：US14443602

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K31/713 ,  A61K31/706 ,  A61K31/437 ,  A61K38/21 ,  G01N33/574 ,  C07K16/40 ,  C07K14/57 ,  C12Q1/68 ,  C12N15/113

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

公开(公告)号：US20150258175A1

公开(公告)日：2015-09-17

申请号：US14443602

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K38/21 ,  C12N15/113 ,  C12Q1/68 ,  G01N33/574 ,  A61K31/437 ,  C07K16/40

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

Abstract translation: 本发明涉及包含组蛋白赖氨酸N-甲基转移酶EZH2（泽斯特同系物2的增强子）抑制剂和干扰素-γ受体活性增强剂的药物组合物。 本发明还涉及治疗患有癌症的患者的方法，包括给药该药物组合物。

公开(公告)号：US20180311264A1

公开(公告)日：2018-11-01

申请号：US15770437

申请日：2016-10-24

Applicant: Agency for Science,Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K31/704 ,  A61P35/00 ,  C12Q1/6886

CPC classification number: A61K31/704 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2800/52

Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.